Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.73% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 13.11M.
Undervalued
The company’s latest PE is -0.84, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.66M shares, increasing 30.25% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 141.56K shares of this stock.